Abstract
B-cell maturation antigen (BCMA) targeted chimeric antigen receptor-T (CAR-T) cells generate short-lived responses in multiple myeloma (MM) with high risk of cytokine release syndrome and neurotoxicity. Expressing CAR proteins on alternative cell types could lead to a less toxic cure. Invariant natural killer T-cells (iNKTs) express a monomorphic T cell receptor that recognizes glycolipids displayed by the MHC-like molecule CD1d. iNKTs do not cause graft versus host disease (GvHD), making them a useful alternative cell type for an allogeneic,
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
